Pipeline Growth Rebounds As Number Of Products In Development Soars Past 16K
There was a welcome increase in the rate of expansion of the pharma and biotech pipeline in 2018, following a couple of years of slowing growth. There are now more than 16,000 products in active development and cancer’s dominance shows no sign of fading.
You may also be interested in...
A first look at the clinical data for Novavax’s COVID-19 vaccine suggests it can produce strong antibody responses while being well tolerated.
A couple of unexpected events for pimavanserin mean that Acadia will drop its development for major depressive disorder and have to wait a little longer to hear if it can launch the product for dementia-related psychosis, a large potential indication.
The US FDA has given the go-ahead for marketing of ViiV healthcare’s novel HIV drug just as the EMA removes the accelerated assessment status from its application there.